An immunohistochemical (IHC) analysis demonstrated that the tumor was moderately positive for estrogen receptor (ER) at 15%, strongly positive for progesterone receptor (PR) at 50%, Ki-67 unfavorable at 30%, and HER2/NEU-positive by fluorescence in situ hybridization (FISH). This evidence concerns the gene ERBB2 and neoplasm.